Abstract: Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. Methods for preparing the drug-loaded microbead compositions and embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads. Additional drug-loaded microbead compositions include microbeads of a biodegradable material, vesicular agents, a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents.

Abstract: Embodiments herein are directed to an occlusion device that includes a body, a pair of lobes, and an adjustment assembly. One of the pair of lobes positioned at a distal portion of the body and the other one is positioned at a proximal portion. The body includes an adjustment assembly positioned between the distal and the proximal portions to change a distance between the pair of lobes. The adjustment assembly includes a receiving member and an elongated member. The elongated member is configured to move the body between an extended position and a retracted position, such that in the retracted position, the elongated member is received within an inner diameter of the receiving member. In the extended position, the elongated member is extended away from a first end of the receiving member such that the distance between the pair of lobes is increased.

Abstract: MEANS FOR SOLVING THE PROBLEMS A rack energy storage apparatus includes a rack, energy storage modules, and first busbars. Each energy storage module includes energy storage cells, a first terminal connector, and a second terminal connector. The first terminal connector extends in a stacking direction of the energy storage modules and is open at ends of the first terminal connector in the stacking direction. The second terminal connector extends in a perpendicular direction and is open at an end in the perpendicular direction. The perpendicular direction is perpendicular to the stacking direction. Each first busbar includes a first end portion and a second end portion. The first end portion extends in the stacking direction and is coupled to the first terminal connector. The second end portion extends in the perpendicular direction and is coupled to the second terminal connector.

Abstract: Embolic compositions include a carrier liquid that solidifies to form a solid occlusion matrix at a target site in a blood vessel, and a dissipatable solid additive contained within the carrier liquid. The dissipatable solid additive includes microparticles that are substantially insoluble in the carrier liquid, that are dispersed in the matrix upon solidification of the matrix, and that are dissipated out of the matrix by action of blood flow in the blood vessel against the matrix. Thereby, the matrix develops a porous structure and the blood vessel at the target site is less than totally occluded after dissipation of the additive. Methods of occluding a blood vessel include injecting the embolic composition to a target site in a blood vessel, allowing the embolic composition to solidify, and allowing the dissipatable solid additive to be dissipated from the solid occlusion matrix by blood flow in the blood vessel.

Abstract: Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. Methods for preparing the drug-loaded microbead compositions and embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads. Additional drug-loaded microbead compositions include microbeads of a biodegradable material, vesicular agents, a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents.

Abstract: Embodiments of the disclosed technologies are capable of evaluating content recommendations. The embodiments describe creating a prompt using a search query and a content recommendation output by a machine learning model in response to the search query. The embodiments further describe causing a LLM to generate an evaluation of the content recommendation and the search query using the prompt. The evaluation includes a relevance score of the content recommendation and the search query. The embodiments further describe training the machine learning model to generate an updated content recommendation in response to the search query. The training includes using the relevance score of the content recommendation and the search query.

Abstract: Medical systems include convenient and secure methods and systems for transferring medical data associated with a unique identity (ID) of a patient from a first patient monitoring device to a second patient monitoring device. The medical data associated with the unique ID includes physiological data of the patient monitored by the first patient monitoring device. At least one computing device in communication with the first patient monitoring device and the second patient monitoring device receives the data associated with the unique ID from the first patient monitoring device, receives the unique ID from the second patient monitoring device, receives a request to transfer the data associated with the unique ID to the second patient monitoring device, and causes the data associated with the unique ID to be transmitted to the second patient monitoring device.

Abstract: The compositions herein are directed to a rubber composition, which contains a polymer crosslinked with methacrylate and polyacrylate, a polysaccharide or gum, and a cellulose base for filling molds.

Abstract: Turning now to the drawings, systems and methods for transferring funds in accordance with embodiments of the invention are illustrated. In one embodiment, a method for conducting peer-to-peer transfers includes obtaining a cash-out request data using a fund transfer server system, wherein the cash-out request data includes target account data and fund data, the target account data includes metadata identifying a consumer account and specifies an account to which funds will be provided, and the fund data describes the funds to be provided in response to redeeming the cash-out request, generating a cash-out code based on cash-out request data using the fund transfer server system, providing the cash-out code using the fund transfer server system, obtaining cash-out code redemption data using the fund transfer server system, wherein the cash-out code redemption data identifies the provided cash-out code, and transmitting a request to provide the funds described by the fund data.

Abstract: Embodiments herein are directed to an occlusion device that includes a body, a pair of lobes, and an adjustment assembly. One of the pair of lobes positioned at a distal portion of the body and the other one is positioned at a proximal portion. The body includes an adjustment assembly positioned between the distal and the proximal portions to change a distance between the pair of lobes. The adjustment assembly includes a receiving member and an elongated member. The elongated member is configured to move the body between an extended position and a retracted position, such that in the retracted position, the elongated member is received within an inner diameter of the receiving member. In the extended position, the elongated member is extended away from a first end of the receiving member such that the distance between the pair of lobes is increased.

Abstract: Embodiments of the disclosed technologies include, responsive to a first use of a first application by a first user, configuring, in a first prompt, at least one instruction based on first application context data and first user context data. The first prompt is stored in a memory that is accessible to the first application and a second application. Via the second application, first output of a generative artificial intelligence (GAI) model is presented to the first user. Based on the first output of the GAI model, at least one second use of the first application by the first user, or at least one first use of a third application by the first user, is configured.

Abstract: The present disclosure relates to formulations for coating a balloon of a balloon catheter, the formulations including one or more groups of microparticles that include a therapeutic agent. In some aspects, the microparticles are polymer microparticles with the therapeutic dispersed therein or crystalline microparticles of the therapeutic agent. In some aspects, the formulations further include an antioxidant and/or an excipient.

Abstract: A vascular occlusion device includes a plurality of radially-extending segments and a plurality of angled bends connecting ends of two or more radially-extending segments of the plurality of radially-extending segments. Each angled bend may define a contact point configured to anchor to a vessel wall. The vascular occlusion device may be configurable between an unexpanded state and an expanded state, and when the vascular occlusion device is in the expanded state, the plurality of angled bends expand such that the contact points contact the vessel wall. The contact points may define a width of the vascular occlusion device in a direction perpendicular to a length of the vascular occlusion device. The width may be configured to correspond to a diameter of a blood vessel.

Abstract: The neuron Logic Gate Metal-Oxide-Semiconductor (?LGMOS) circuits to mimic neurons' “integrate-and-fire” behaviors in biological neural network system can be fabricated with industry Complementary Metal-Oxide Semiconductor (CMOS) logic process technology, with which digital computational circuits are fabricated. A processing system having analog ?LGMOS circuits, conversion circuitry and digital circuits optimized for power and cost for varieties of applications can be then fabricated with the same CMOS logic process technology for IC chips. Meanwhile analog ?LGMOS circuits inspired from biological neural network systems can be simulated, designed, and fabricated for IC chips for the applications of biomedical fields.

Abstract: The present disclosure concerns drug coating layers for medical devices that cover an exterior surface or portion thereof. The drug coating layers include a bioabsorbable material with a therapeutic or a polymer microparticle loaded with a therapeutic embedded therein. As the material is bioabsorbed the therapeutic is released and available to provide localized activity in a subject. In some aspects, the drug coating layer is of a material that due to the body temperature of the subject becomes tacky and allows for adhesion to the vessel wall.

Abstract: In some implementations, a system may receive, from a first user, data associated with a new database entry to be added to a master database that is associated with multiple sets of users having different access permissions to entries in the master database. The system may write the data to a first repository, write an entry including the data to a master repository, and generate a record of the entry. The system may receive, from a second user, additional data associated with the new database entry. The system may write the additional data to a second repository, modify the entry in the master repository based on the additional data, and generate a record of the modified entry. The system may perform verifications and output a notification based on the verifications. The system may further output, to a public repository, the modified entry with at least one data value removed.

Abstract: A variable gain amplifier system includes a variable gain amplifier circuit configured to receive an input signal, apply a gain to the input signal, and generate an output signal in accordance with the gain applied to the input signal. The variable gain amplifier circuit is further configured to receive a gain control signal and a bandwidth control signal. A control module is configured to generate the gain control signal to adjust the gain of the variable gain amplifier circuit and generate, separately from the gain control signal, the bandwidth control signal to adjust a bandwidth of the variable gain amplifier circuit by selectively varying an amount of inductance contributed by an inductor circuit of the variable gain amplifier circuit.

Abstract: Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. Methods for preparing the drug-loaded microbead compositions and embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads. Additional drug-loaded microbead compositions include microbeads of a biodegradable material, vesicular agents, a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents.

Abstract: In some implementations, a system may receive, from a first user, data associated with a new database entry to be added to a master database that is associated with multiple sets of users having different access permissions to entries in the master database. The system may write the data to a first repository, write an entry including the data to a master repository, and generate a record of the entry. The system may receive, from a second user, additional data associated with the new database entry. The system may write the additional data to a second repository, modify the entry in the master repository based on the additional data, and generate a record of the modified entry. The system may perform verifications and output a notification based on the verifications. The system may further output, to a public repository, the modified entry with at least one data value removed.

Abstract: Drug-loaded microbead compositions include microbeads of a biodegradable material and vesicular agents located within or associated with the biodegradable material of the microbeads. The vesicular agents include a lipid bilayer and comprise liposomes or ethosomes. The drug-loaded microbeads include a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.